Product Description

Bonqat 50 mg/ml Oral Solution is indicated for a single, specific behavioural indication in cats. It is not licensed for continuous or repeated daily use, and must only be used in cats for whom its use has been assessed as appropriate by the prescribing veterinarian.

For Cats:

Alleviation of acute anxiety and fear associated with transportation and veterinary visits

The product is administered as a single oral dose of 5 mg/kg bodyweight (0.1 ml/kg) approximately 1.5 hours before the start of transportation or the planned veterinary visit. It may be administered directly into the mouth or mixed with a small amount of food. Large amounts of food may delay the onset of effect. An oral syringe graduated in 0.1 ml increments is provided in the pack.

The prescribing veterinarian should advise the owner to always inform the attending veterinarian if Bonqat has been administered to the cat prior to the veterinary visit.

Which Animals Can Use Bonqat?

Bonqat 50 mg/ml Oral Solution is licensed for use in cats only. It must not be used in animals with known hypersensitivity to pregabalin or to any of the excipients. The safety of this product has not been established in cats weighing less than 2 kg, younger than 5 months, or older than 15 years; use in these animals should only be considered on the basis of a veterinary benefit-risk assessment. The safety of this product has only been established in healthy cats or those with mild systemic illness; it has not been established in animals with moderate or severe systemic disease, including moderate to severe renal, liver or cardiovascular disease. Always ensure a valid prescription is in place before ordering.

Available Strengths & Sizes

Please order as directed on your veterinary prescription. Bonqat Oral Solution for Cats is available in a single strength and pack size.

Directions for Use

This is a prescription medication and must be used exactly as directed by your veterinary surgeon. The cat's health status should always be assessed before the product is prescribed. Administer orally as a single dose of 5 mg/kg bodyweight (0.1 ml/kg) approximately 1.5 hours before the start of transportation or the planned veterinary visit, using the oral syringe provided. The product can be given directly into the mouth or mixed with a small amount of food; large amounts of food may delay onset of action.

Do not re-dose if the cat spits part of the dose, vomits after treatment, or shows hypersalivation, or if the product does not appear to have any effect.

The effect can last approximately 7 hours. If the cat appears drowsy or shows signs of exaggerated effects after administration, keep the cat indoors and do not offer food or water until the cat has fully recovered. If the cat seems uncoordinated or overly tired, keep it warm.

Contraindications

Source: SPC Section 3.3

Do not use in cases of hypersensitivity to the active substance (pregabalin) or to any of the excipients (including sodium benzoate)

Storage & Handling

Store in a refrigerator (2 °C–8 °C). Keep in the original packaging. Keep out of the sight and reach of children and animals at all times. Shelf life as packaged for sale: 3 years. After first opening: 6 months when stored in a refrigerator; the opened bottle may be stored for short periods (up to 1 month in total) at or below 25 °C.

⚠ Controlled Drug storage: As a Schedule 3 Controlled Drug, Bonqat must be stored in accordance with the Misuse of Drugs (Safe Custody) Regulations and applicable veterinary legislation. Please refer to your veterinary prescription for specific guidance.

Withdrawal period:

Not applicable. Bonqat is not for use in food-producing animals.

Important Warnings

Source: SPC Section 3.5

Always assess the cat's health status before prescribing this product

Safety has not been established in cats weighing less than 2 kg, younger than 5 months, or older than 15 years; use only on the basis of a veterinary benefit-risk assessment

Safety has only been established in healthy cats or those with mild systemic illness; it has not been established in cats with moderate or severe renal, hepatic or cardiovascular disease

This product may cause a slight reduction in heart rate, respiratory rate and body temperature; the treated animal should be kept at a suitable ambient temperature after administration

Monitor the cat carefully for respiratory depression and sedation if any CNS depressant is used at the same time as pregabalin, as the effects may be potentiated; an appropriate dose adjustment should be made

The prescribing veterinarian should advise the owner to always inform the attending veterinarian if Bonqat has been administered prior to the visit

Do not re-dose if the cat spits part of the dose, vomits, shows hypersalivation, or if the product does not appear effective

If exaggerated sedation or ataxia occurs, keep the cat indoors, warm and without food or water until fully recovered

Safety during pregnancy, lactation and in breeding animals has not been established in the target species; laboratory studies in rats and rabbits have shown embryofoetotoxic and maternotoxic effects with repeated high-dose pregabalin. Use only on the basis of a veterinary benefit-risk assessment

Human safety — systemic effects: Exposure to pregabalin may cause adverse effects in humans including dizziness, tiredness, ataxia, blurred vision and headache

Human safety — skin, eye and mucosal contact: Avoid skin, eye or mucosal contact. Wash hands thoroughly immediately after administration. In case of accidental skin contact, wash with soap and water and remove contaminated clothing. In case of accidental eye or mucosal contact, flush with water

Human safety — accidental ingestion: In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician. Do not drive, as tiredness may occur

Human safety — seek advice: If symptoms such as dizziness, tiredness, ataxia or blurred vision occur following any contact with this product, seek medical advice

Schedule 3 Controlled Drug Notice

Bonqat 50 mg/ml Oral Solution contains pregabalin, which is classified as a Schedule 3 Controlled Drug under the Misuse of Drugs Regulations 2001 (as amended) in the UK. The supply of this product is subject to additional legal requirements applicable to Controlled Drugs, including prescription requirements, record-keeping obligations and, in some circumstances, safe custody requirements. A valid veterinary prescription from a registered veterinary surgeon is required before this product can be dispensed.

POM-V Prescription Notice

This product is a Prescription Only Medicine — Veterinary (POM-V). It may only be supplied by a veterinary surgeon or, when prescribed by a veterinary surgeon, by a pharmacist or SQP. A valid veterinary prescription is required before this product can be dispensed.

MA Number: Vm 06043/5003 (UK GB) | Source: VMD Product Information Database (vmd.defra.gov.uk)